PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26509262-4	2015	Androgen-independent prostate cancer cells were more prone to activate a Wnt-reporter, and inhibition of the Wnt/beta-catenin pathway increased sensitivity of these cells to the second-generation antiandrogen, enzalutamide.	enzalutamide	210-222	catenin beta 1	Homo sapiens	113-125	
33441906-0	2021	Regulation of carcinogenesis and mediation through Wnt/beta-catenin signaling by 3,3"-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.	enzalutamide	109-121	catenin beta 1	Homo sapiens	55-67	
30928160-8	2019	GSEA identified the Wnt/beta-catenin pathway as the top differentially modulated pathway among enzalutamide-resistant patients.	enzalutamide	95-107	catenin beta 1	Homo sapiens	24-36	
30928160-9	2019	Furthermore, beta-catenin mutations were exclusive to enzalutamide-resistant patients (p=0.01) and independently predictive of poor OS (median 13.6 vs 41.7mo; p=0.025).	enzalutamide	54-66	catenin beta 1	Homo sapiens	13-25	
30928160-11	2019	The Wnt/beta-catenin pathway plays an important role in enzalutamide resistance, with differential pathway expression and enrichment of beta-catenin mutations in enzalutamide-resistant patients.	enzalutamide	56-68	catenin beta 1	Homo sapiens	8-20	
30928160-11	2019	The Wnt/beta-catenin pathway plays an important role in enzalutamide resistance, with differential pathway expression and enrichment of beta-catenin mutations in enzalutamide-resistant patients.	enzalutamide	162-174	catenin beta 1	Homo sapiens	8-20	
30928160-11	2019	The Wnt/beta-catenin pathway plays an important role in enzalutamide resistance, with differential pathway expression and enrichment of beta-catenin mutations in enzalutamide-resistant patients.	enzalutamide	162-174	catenin beta 1	Homo sapiens	136-148	
31126320-7	2019	Additionally, the combination of enzalutamide with USP14 inhibition/knockdown induced significant downregulation of AR proteins and suppression of AR-related signaling pathways, including Wnt/beta-catenin and PI3K/AKT pathways.	enzalutamide	33-45	catenin beta 1	Homo sapiens	192-204	
30684266-5	2019	In addition, PLCepsilon knockdown partly restored the sensitivity of drug-resistant cells to bicalutamide and enzalutamide by inhibiting the activity of the wnt3a/beta-catenin/AR signaling axis.	enzalutamide	110-122	catenin beta 1	Homo sapiens	163-175	
29700003-7	2018	These data identify activation of the Wnt/beta-catenin pathway as a major mechanism contributing to enzalutamide resistance and demonstrate the potential to stratify patients with high risk of said resistance.Significance: Wnt/beta-catenin inhibition resensitizes prostate cancer cells to enzalutamide.	enzalutamide	100-112	catenin beta 1	Homo sapiens	42-54	
29700003-7	2018	These data identify activation of the Wnt/beta-catenin pathway as a major mechanism contributing to enzalutamide resistance and demonstrate the potential to stratify patients with high risk of said resistance.Significance: Wnt/beta-catenin inhibition resensitizes prostate cancer cells to enzalutamide.	enzalutamide	100-112	catenin beta 1	Homo sapiens	227-239	
29700003-7	2018	These data identify activation of the Wnt/beta-catenin pathway as a major mechanism contributing to enzalutamide resistance and demonstrate the potential to stratify patients with high risk of said resistance.Significance: Wnt/beta-catenin inhibition resensitizes prostate cancer cells to enzalutamide.	enzalutamide	289-301	catenin beta 1	Homo sapiens	42-54	
29700003-7	2018	These data identify activation of the Wnt/beta-catenin pathway as a major mechanism contributing to enzalutamide resistance and demonstrate the potential to stratify patients with high risk of said resistance.Significance: Wnt/beta-catenin inhibition resensitizes prostate cancer cells to enzalutamide.	enzalutamide	289-301	catenin beta 1	Homo sapiens	227-239	
29700003-0	2018	Inhibition of the Wnt/beta-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.	enzalutamide	67-79	catenin beta 1	Homo sapiens	22-34	
29700003-3	2018	Bioinformatics analysis predicted that activation of the Wnt/beta-catenin pathway and its interaction with AR play a major role in acquisition of enzalutamide resistance.	enzalutamide	146-158	catenin beta 1	Homo sapiens	61-73	
29700003-4	2018	To validate the finding, we show upregulation of beta-catenin and AR in enzalutamide-resistant cells, partially due to reduction of beta-TrCP-mediated ubiquitination.	enzalutamide	72-84	catenin beta 1	Homo sapiens	49-61